In adults with overweight or obesity, 8 participants on liraglutide 3.0 mg had adjudicated cardiovascular events versus 10 in the comparators group, with lower event rates on liraglutide.
In plain wordsIn adults with overweight or obesity, 8 people on liraglutide and 10 on placebo or orlistat had heart events; the gap was not statistically clear.
- Peptide
- Liraglutide
- Outcome
- DecreasePositively adjudicated cardiovascular events (rate)
- Study
n = 5,908
- Comparator
- Placebo or orlistat
- Analysis
- Primary
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- 3.0 mgAs given in this study (human).
Measurements
- Event rate
- 1.54 events/1000 person-years
- liraglutide 3.0 mg
- Event rate
- 3.65 events/1000 person-years
- comparators
Source sentences
With liraglutide 3.0 mg, 8 participants had positively adjudicated cardiovascular events (1.54 events/1000 person-years) compared to 10 participants in the comparators group (3.65 events/1000 person-years).
1 context sentence(design, population, supporting numbers)
The cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management at a dose of 3.0 mg, was evaluated post hoc using data from 5908 participants in 5 randomized, double-blind, placebo-controlled clinical trials.